CF
AVXL icon

Corebridge Financial’s Anavex Life Sciences AVXL Stock Holding History

Corebridge Financial’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-36,760
Closed -$315K – 279
2025
Q1 		$315K Sell
36,760
-546
-1% -$5.16K ﹤0.01% 1828
2024
Q4 		$401K Sell
37,306
-2,815
-7% -$21.7K ﹤0.01% 1798
2024
Q3 		$228K Buy
40,121
+958
+2% +$5.53K ﹤0.01% 2157
2024
Q2 		$165K Buy
+39,163
New +$158K ﹤0.01% 2316

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NL
NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Corebridge Financial's AVXL Position: Q2 2025 in Review

Corebridge Financial sold out of Anavex Life Sciences (AVXL) in Q2 2025, closing a stake of 36,760 shares — an estimated $315K sold.

Corebridge Financial first reported a position in AVXL in Q2 2024 and held it in 4 quarters. The position peaked at $401K in Q4 2024. 178 funds tracked by Wall St. Rank hold AVXL as of Q2 2025.

  • Corebridge Financial reported no remaining Anavex Life Sciences position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 36,760 Anavex Life Sciences shares in Q2 2025, an estimated $315K.
  • Corebridge Financial first reported a position in Anavex Life Sciences in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Anavex Life Sciences position peaked at $401K in Q4 2024.
  • 178 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.